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Type 1 diabetes is an autoimmune disorder that is character-
ized by a failure of the unfolded protein response in islet  cells
with subsequent endoplasmic reticulum stress and cellular
death. Thiazolidinediones are insulin sensitizers that activate
the nuclear receptor PPAR- and have been shown to partially
ameliorate autoimmune type 1 diabetes in humans and non-
obese diabetic (NOD) mice. We hypothesized that thiazolidin-
ediones reduce  cell stress and death independently of insulin
sensitivity. To test this hypothesis, female NOD mice were
administered pioglitazone during the pre-diabetic phase and
assessed for insulin sensitivity and  cell function relative to
controls. Pioglitazone-treated mice showed identical weight
gain, body fat distribution, and insulin sensitivity compared
with controls. However, treated mice showed significantly
improved glucose tolerance with enhanced serum insulin levels,
reduced  cell death, and increased  cell mass. The effect of
pioglitazonewas independent of actions onTcells, as pancreatic
lymph node T cell populations were unaltered and T cell prolif-
eration was unaffected by pioglitazone. Isolated islets of treated
mice showed a more robust unfolded protein response, with
increases in Bip and ATF4 and reductions in spliced Xbp1
mRNA. The effect of pioglitazone appears to be a direct action
on  cells, as islets frommice treated with pioglitazone showed
reductions in PPAR- (Ser-273 ) phosphorylation. Our results
demonstrate that PPAR- activation directly improves  cell
function and survival in NOD mice by enhancing the unfolded
protein response and suggest that blockadeofPPAR- (Ser-273)
phosphorylation may prevent type 1 diabetes.
Type 1 diabetes (T1D)2 is characterized by the loss of insulin
production, as  cells succumb to targeted autoimmunity. The
non-obese diabetic (NOD)mouse spontaneously develops T1D
and is used as amodel that closelymimics human disease (1). In
this animalmodel insulitis (infiltration of the islet by cells of the
immune system) is observed as early as 4 weeks of age, with the
subsequent development of diabetes inmany animals by 12–20
weeks of age (2). The concept that the only defect in T1D lies in
the immune system has been revisited in recent years. Our
group and others have demonstrated that endoplasmic reticu-
lum (ER) stress and resultant insulin secretory defects in the 
cell precede the onset of T1D inmice (3, 4). These findings raise
the intriguing possibility that ER stress in the  cell might con-
tribute to the aberrant production of “neoantigens” that subse-
quently invites autoimmunity and insulitis (5–7). Dysfunction
of the  cell in pre-T1D has been observed in other studies in
NOD mice (8), and both  cell ER stress and dysfunction have
been observed in humanswith early T1Dor destined to develop
T1D (9, 10). Therefore, therapies that directly enhance the ER
stress-remediating response known as the unfolded protein
response (UPR) may prove useful as adjunctive therapies to
delay/prevent T1D.
Thiazolidinediones (TZDs) are activators of the nuclear
transcription factor peroxisome proliferator-activated recep-
tor- (PPAR-) and have been traditionally viewed as insulin
sensitizers, due to their effects on adipose tissue. The anti-dia-
betic action of TZDs in adipose tissue occurs, in part, by block-
ing the phosphorylation of PPAR- at Ser-273 (11). Addition-
ally, studies in humanswith type 2 diabetes (T2D) and in rodent
models of T2D suggest that TZDs may also directly enhance 
cell function (12, 13). In addition to their potential effects on 
cells, TZDs have also been implicated in the reduction of
inflammation and autoimmunity due to the effects on dendritic
cells, macrophages, and T cells of the immune system (14–16).
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The potential utility of TZDs in T1D has been limited to only
a few studies. In humans, treatment of establishedT1Dwith the
TZD pioglitazone resulted in modest improvements in glyce-
mic control (17–19), raising the prospect that interventionwith
the drug in the pre-diabetic phasemight have greater impact. In
accordance with this possibility, studies in NOD mice have
shown that administration of the TZDs rosiglitazone and tro-
glitazone at the time of weaning significantly reduced the inci-
dence of T1D (20, 21). These studies in NOD mice did not
address the possibility that direct effects of TZDs on the  cell
may have led to reduced  cell stress early in the pathogen-
esis of T1D. To address this possibility, we studied the effects
of pioglitazone in the pre-diabetic phase in NOD mice. Our
results were consistent with a  cell sparing effect of piogli-
tazone independent of effects on insulin sensitivity or body
fat distribution and suggest that reductions in early  cell
stress in NOD mice may underlie the reduction in T1D inci-
dence caused by TZDs.
Results
TZD Therapy Improves Glycemic Control in Pre-diabetic
Female NODMice—Pre-diabetic female NODmice show pro-
gressively worsening  cell function, failing UPR, and increas-
ing ER stress in pancreatic islets as they age from 6 weeks
onward (3, 4, 8). To determine if TZD therapy can restore the
UPR and ameliorate  cell stress in the pre-diabetic phase,
6-week-old female NOD mice were fed a standard chow diet
containing pioglitazone (0.01 wt%) until 10 weeks of age. Con-
trol mice were fed an identical diet not containing pioglitazone.
By design, none of the animals developed overt diabetes
(defined as blood glucoses on two consecutive measurements
250 mg/dl) during the course of the study. Whereas pioglita-
zone is known to increase body weight and fat mass in mouse
models of T2D (22), during this study pioglitazone-treated
NODmice gained weight no differently than controls (Fig. 1A)
and demonstrated no differences in body fat composition as
determined by dual-energy x-ray absorptiometry scanning at
the endof the study (Fig. 1,B,C, andD).Nevertheless, at the end
of the study, pioglitazone-treated mice exhibited a significant
improvement in glycemic control compared with control mice,
as judged by an intraperitoneal glucose tolerance test (GTT)
and corresponding area under the curve (AUC) analysis (Fig. 1,
E and F). To assess if the improved glycemic control in piogli-
tazone-treated mice was caused by altered insulin sensitiv-
ity, an intraperitoneal insulin tolerance test was performed,
revealing no differences in insulin sensitivity between the
two groups (Fig. 1, G and H). Additionally, phosphorylation
of Akt in liver and muscle after acute intraperitoneal insulin
administration revealed no differences between control and
pioglitazone-treated mice (Fig. 1I). Taken together, these
results suggest that pioglitazone improves glucose tolerance
in NOD mice without significant changes in tissue insulin
sensitivity.
Pioglitazone Treatment Reduces Insulitis in NOD Mice but
Does Not Affect T Cell Proliferation in Vitro—To determine if
the improved glycemic profile in pioglitazone-treated mice
emanated from alterations to the immune response, we next
assessed insulitis in histological sections of pancreas from
treated and control mice. Fig. 2, A and B, shows that pioglita-
zone treatment reduced the incidence and severity of insulitis
compared with controls. To test whether the reduction in insu-
litis might have been caused by an effect of pioglitazone on T
cell populations, we isolated pancreatic lymph nodes frommice
and assessedCD4T cell populations in these tissues. Notably,
pioglitazone had no significant effect on Th1, Th17 (CD4
IL17A), or Treg (CD4CD25Foxp3) cell populations in
the pancreatic lymph node (Fig. 2, C–E).
The reductions in insulitis without effects on specific CD4
T cell populations led us to consider if pioglitazone might have
caused a generalized reduction in T cell proliferation. Unfrac-
tionated splenocytes fromNODmice were loaded with the dye
carboxyfluorescein succinimidyl ester (CFSE) and subjected to
polyclonal stimulation using a combination of anti-CD3 anti-
body, anti-CD28 antibody, and IL-2 in vitro to mimic antigen-
dependent and -independent signals as seen in T1D (23). After
4 days stimulation in the presence or absence of 1 or 10 M
pioglitazone, cells were gated for CD4 positivity and analyzed
for CFSE dilution by flow cytometry. Fig. 3A shows representa-
tive histograms demonstrating dilution of CFSE upon stimula-
tion with anti-CD3/anti-CD28/IL-2, findings indicative of T
cell proliferation. No differences in CFSE dilution were
observed with either 1M or 10M pioglitazone (Fig. 3B), indi-
cating that pioglitazone at these concentrations does not alter
the proliferative rate of T cells. These data suggest that the
reduction in insulitis seen in treated mice is not likely an effect
of pioglitazone to directly alter T cell populations or suppress T
cell proliferation.
Pioglitazone Inhibits PPAR- (Ser-273) Phosphorylation in 
Cells and Islets—Pioglitazone and related TZDs interact with
PPAR- and block phosphorylation of Ser-273, an effect that
promotes actions of the nuclear receptor (11). To confirm a
direct effect of pioglitazone in islet  cells, we pretreated the
mouse  cell-derived cell lineMIN6with 10M pioglitazone or
10 M roscovitine (an inhibitor of cyclin-dependent kinases,
which are known to promote Ser-273 phosphorylation) (24)
then performed an immunoblot for phospho-PPAR- (Ser-
273). As shown in Fig. 4A, levels of phospho-PPAR- (S273)
was detectable in non-treated (control) cells. By contrast, phos-
pho-PPAR- (S273) levels were blunted in cells pretreated with
10 M pioglitazone and 10 M roscovitine (Fig. 4A). Islets of
pioglitazone-treated NOD mice also showed reductions in
phospho-PPAR- (S273) (Fig. 4B), consistent with a direct
effect of pioglitazone on islets.
TZDTherapy Augments Insulin Secretion and ReducesCell
ER Stress and Death in Pre-diabetic Female NOD Mice—To
determine if the improved glycemic control in pioglitazone-
treated NODmice was a consequence of enhanced  cell func-
tion, serum insulin levels were measured after an intraperito-
neal glucose load. As shown in Fig. 5A, pioglitazone-treated
mice displayed significantly higher levels of serum insulin com-
pared with the control group at 10min after the intraperitoneal
glucose load. Isolated islets from treated mice also showed a
lower basal insulin secretion at low glucose (2.5 mM) in vitro
and a significantly more robust response to glucose stimulation
(25 mM) compared with control islets (Fig. 5B). To assess if
pioglitazone treatment affected  cell stress and prohormone
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processing, we nextmeasured random-fed insulin and proinsu-
lin and the proinsulin:insulin ratio. Higher proinsulin:insulin
ratios have been shown to correlate to  cell ER stress in both
humans andNODmice (4, 25, 26). As shown in Fig. 5C, whereas
the random-fed insulin was a significant 2-fold greater in the
treatment group compared with controls, the proinsulin levels
were not significantly different (Fig. 5D), resulting in a proin-
sulin:insulin ratio that trended lower (p  0.07) in the treat-
ment group (Fig. 5E).
To assess more directly the possibility that pioglitazone
enhanced theUPR and reducedER stress, we next isolated islets
from treated and control mice at the end of the study and mea-
sured bothmRNA and proteinmarkers of the UPR. The UPR is
characterized by variable activation of three distinct pathways,
IRE1, PERK, and ATF6. In islet  cells, the IRE1 and PERK
pathways predominate and are evident by increases in spliced
Xbp1 mRNA levels and ATF4 protein levels (27). As shown in
Fig. 6A, there was significant reduction in splicedXbp1 (sXbp1)
mRNA levels in islets from pioglitazone-treated mice com-
pared with controls, demonstrating attenuation of the IRE1
pathway by pioglitazone treatment. By contrast, an increase in
ATF4 protein levels was observed by immunoblot analysis (Fig.
6B). The elevation of ATF4 protein levels was confirmed by an
increase in the mRNA encoding DNA damage-inducible pro-
tein 34 (Gadd34), a known ATF4 target gene (Fig. 6C) (28).
GADD34 is a phosphatase that dephosphorylates eIF2 to
restore protein synthesis in the remediation phase of the UPR
(28, 29). As shown in Fig. 4B, phosphorylated eIF2 is reduced
in islets of pioglitazone-treated mice. Consistent with the
recovery of protein synthesis, a slight, but significant, increase
in the levels of the protein folding chaperone BIP was observed
in the islets of treated mice (Fig. 6C).
FIGURE 1. Effect of pioglitazone treatment on metabolic parameters in pre-diabetic NOD mice. 6-Week-old pre-diabetic NOD mice (n 10 per group)
were placed on either normal chow (Control) or chow containing 0.01wt%pioglitazone (Pio).A, bodyweights during feeding. B, lean bodymass as assessedby
dual-energy x-ray absorptiometry after 4 weeks of feeding. C, fat mass as assessed by dual-energy x-ray absorptiometry after 4 weeks of feeding. D, percent
body fat as assessed by dual-energy x-ray absorptiometry after 4 weeks of feeding. E, results of intraperitoneal GTT after 4 weeks of feeding. F, AUC analysis of
GTT shown in panel E.G, results of intraperitoneal insulin tolerance test after 4weeks of feeding.H, AUC analysis of corresponding ITT in panel G. I, immunoblot
analysis of phospho-AKT (Ser-473) and total AKT in liver andmuscle isolated from 4-week-fedmice after acute insulin injection. Immunoblots show represen-
tative data from three mice per group (Control and Pio). * indicates that the value is significantly different from control by two-tailed t test.
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Failure of the UPR to adapt to the underlying stress leads to
frank ER stress and to activation of the proapoptotic pathway
mediated by CHOP (30). Concordant with the adaptive UPR in
pioglitazone-treated mice, there was a reduction in Chop
mRNA in islets (Fig. 6E) and a corresponding reduction in
CHOP protein in  cells by immunohistochemistry (Fig. 7A).
Likewise, cleaved caspase 3 (CC3), a marker of apoptotic cells,
was reduced in insulin cells of pioglitazone-treated mice
compared with control mice (Fig. 7B).
To clarify the underlying mechanism promoting an adaptive
UPR, we evaluated pancreas tissue sections for evidence of oxi-
dative stress, which is known to drive the development of ER
stress (27). Fig. 7C shows that control NOD mice exhibited
evidence of oxidative stress in islets, as assessed by immuno-
staining for 4-hydroxynonenal (4-HNE). By contrast, minimal
to no 4-HNE staining was observed in islets of pioglitazone-
treated mice. As a likely consequence of reduced oxidative
stress andmore robust UPR,  cell area (as a percentage of total
pancreatic area) was increased 2-fold upon pioglitazone treat-
ment (Fig. 7D). This greater  cell area percent in pioglitazone-
treated mice resulted primarily from reduced  cell death and
not an increase in cell proliferation, as cell death parameters
CC3 (Fig. 7C) and unmethylated preproinsulin DNA (Fig. 7E)
(31) were reduced, but no changes in the proliferation marker
proliferating cell nuclear antigen (PCNA) were observed (Fig.
7F).
Discussion
T1D develops as a disorder of the immune system in which 
cell autoantigens, released as a result of  cell death, trigger the
eventual selection and proliferation of autoreactive T cell
clones (32). It has been speculated that the physiologic early
turnover of  cells seen in neonatal mice (and possibly humans,
as well) might contribute sufficient antigen exposure to trigger
autoimmunity (33), but this possibility has been challenged in
studies of NOD mice (34). A second hypothesis suggests that
stress responses intrinsic to the  result in the pathologic for-
mation of epitopes (asmisfolded or postranslationallymodified
proteins) that are immunogenic (5, 6, 35). In this regard,  cell
ER stress has been shown to occur in the early pre-diabetic
phase in NODmice and in humans with new-onset T1D (4, 10,
25). The UPR is a coordinated response that is activated under
a variety of stress conditions that put increased burden on the
ER (ER stress). Twophases of theUPRhave been recognized: an
adaptive, stress-remediating phase, and a subsequentmaladap-
tive, pro-apoptotic phase that is initiated when remediation is
not possible (for a review, see Ref. 29).
FIGURE 2. Effect of pioglitazone on the frequency and severity of insulitis in pre-diabetic NODmice. 6-Week-old pre-diabetic NODmice were placed on
either normal chow (Control) or chow containing 0.01 wt% pioglitazone (Pio). After 4 weeks of feeding, pancreas and pancreatic lymph nodes were harvested
from animals (n  5 per group). A, representative images of islets stained for glucagon, insulin, and nuclei (DAPI) from control- and pioglitazone-treated
animals; the dense blue nuclei (region indicated by arrows) represent immune infiltrate (insulitis), B, results of insulitis scoring of control- and pioglitazone-
treated animals.C, flow cytometric analysis frompancreatic lymphnodes showingTreg cells (CD4CD25Foxp3) as a percentageof total CD4 cells.D, flow
cytometric analysis from pancreatic lymph nodes showing Th1 cells (CD4IFN-) as a percentage of total CD4 cells. E, flow cytometric analysis from
pancreatic lymph nodes showing Th17 cells (CD4IL17A) as a percentage of total CD4 cells.
FIGURE 3. Proliferation of splenocytes in response to pioglitazone treat-
ment in vitro. Unfractionated NOD mouse splenocytes were stimulated in
vitrowith anti-CD3/anti-CD28 and IL-2 for 4 days thengatedonCD4 cells by
flow cytometry. A, CFSE dye fluorescence intensity in unstimulated (red line)
and stimulated (blue line) CD4 cells in the absence of pioglitazone. B, effects
of 0M (blue line), 1M (red line), and 10M (green line) pioglitazone on CFSE
fluorescence intensity in stimulated CD4 cells.
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The adaptation to ER stress by enhancing the UPR has been
proposed as viable,  cell-protective therapy for T1D (3).
Because administration of TZDs has been shown to ameliorate
ER stress (22), we asked if TZDs have the potential to directly
impact  cell function and survival in NOD mice.
TZDs are traditionally viewed as insulin sensitizers, but evi-
dence in recent years suggests that they have direct effects on
the  cell. These effects include the stimulation of Pdx1 gene
activity and increases in Pdx1 protein levels in isolated  cells
(36, 37), stimulation of Serca2 gene activity and protein levels
(22, 38), and reductions in  cell oxidative stress (39). More-
over, TZD administration was shown to delay the incidence of
T1D in NODmice (20, 21) and to improve T1D glycemic con-
trol in humans (17–19), although it is unclear if these findings
were a result of  cell effects of TZDs. Notably, our studies
showed that pioglitazone administration resulted in a reduc-
tion in phospho-PPAR- (Ser-273) in islets and an improve-
ment in the islet UPR, as evidenced by enhanced ATF4 and BIP
protein levels and a trend to reduced proinsulin:insulin ratio.
Although our study points to a PPAR--dependent effect of
pioglitazone, we should point out that pioglitazone was also
shown to have an acute effect of reducing metabolic flux and
insulin secretion in cells in a non-PPAR--dependent fashion
(40, 41). This effect may have allowed for reduced ER load early
in disease pathogenesis and subsequent improvements in ER
function. Nevertheless, because our findings were not accom-
panied by changes in body weight, body fat distribution, or
insulin sensitivity, we believe they suggest a direct effect of
pioglitazone on islet  cells.
It is noteworthy that we observed increased ATF4 levels
despite a reduction in CHOP protein and mRNA in pioglita-
zone-treated mice. Whereas prior studies have linked ATF4 to
activation of the gene encoding CHOP (42), it has become
increasingly appreciated that other pathways and transcription
factorsmay activate CHOP independently of ATF4 (43, 44) and
that of GADD34 may dissociate ATF4 from Chop activation
(45). We, therefore, propose that the elevation of ATF4 in our
study likely represents an adaptive, ameliorative effect on ER
stress.
A significant outcome in our studies was the increased area
percent of  cells in pioglitazone-treated animals compared
with controls. Importantly,  cell area was also higher in these
animals when compared with 6-week-old NOD mice at the
start of the study, suggesting that pioglitazone treatment either
enhanced the rate of cell replication or reduced cell death or
some combination of the two. This result is reminiscent of
studies in type 2 diabetic db/db mice in which pioglitazone
treatment resulted in increased  cell area that was coincident
with improved glycemic control (22). In our case, pioglitazone-
treated mice showed a reduction in the serum unmethylation
index, a sensitive biomarker of  cell death (31), as well as CC3
staining in insulin cells. In light of the reduction in  cell
death, it is noteworthy that we observed reductions in both
oxidative stress (by 4-HNE immunostaining) and IRE1 activ-
ity (as judged by reduced spliced Xbp1 mRNA). IRE1 is an
endoribonuclease that operates in a bifunctional manner, ini-
tially promoting the adaptive response of the UPR by leading to
Xbp1 splicing and later, during prolonged ER stress, promoting
the cleavage of other mRNAs and microRNAs and leading to
cellular apoptosis (46–48). In prior studies, our group demon-
strated that NOD mice show significant elevations in spliced
Xbp1mRNA (and, by inference, IRE1 activity) compared with
non-diabetes-prone controls at 10–12 weeks of age (4). The
studies of Kaufman et al. (27) suggest that oxidative stress is
closely linked to ER stress. We suggest here that the reductions
in IRE1 activity as a result of attenuated oxidative stress by
pioglitazone likely reflect an augmented and more successful
UPR.
Finally, we should comment on the significant reduction in
insulitis we observed upon pioglitazone treatment. Despite the
reduction in insulitis, we did not observe differences in relative
proportions of CD4T cell subtypes in the draining pancreatic
lymph node. These findings raise the possibility that pioglita-
zonemay have had a primary effect on reducing proliferation of
T cells. We tested this possibility by performing T cell activa-
tion assays in vitro wherein no changes in CD4 cell prolifera-
tion or differentiation were observed in response to pioglita-
zone. Studies have shown stimulatory and inhibitory effects of
FIGURE 4. Pioglitazone suppresses PPAR- (Ser-273) phosphorylation in
 cells in vitro and in islets of NODmice in vivo. A, MIN6 cells were prein-
cubated in vehicle, 10 M pioglitazone (Pio), or 10 M roscovitine overnight,
thenextractswere subjected to immunoblottingusinganti-phospho-PPAR-
(S273) and anti-acetyl-histone H3 (Lys-14) as a loading control. Representa-
tive immunoblots are shown, and thebar graphbelow shows thequantitation
of immunoblots (normalized to loading control) from three independent
experiments. * indicates that the value is significantly different (p  0.05)
compared with vehicle-treated (control) cells. B, 6-week-old pre-diabetic
NOD mice were placed on either normal chow (Control) or chow containing
0.01 wt% pioglitazone (Pio). After 4 of weeks feeding, islets from 2 mice per
group were isolated and subjected to immunoblotting using anti-phospho-
PPAR- (S273), anti-phospho-eIF2, and anti-acetyl-histone H3 (Lys-14) as a
loading control.
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PPAR- on Treg and Th17 cells, respectively (14, 49), so we
cannot rule out the possibility that differences in CD4 T cell
subpopulations occurred in the immediate vicinity of the islets
themselves. In the absence of a direct effect of pioglitazone onT
cell proliferation, it nevertheless remains possible that the
augmentation of the  cell UPR with pioglitazone may have
diminished the stimulus for autoimmunity. In this regard
recent studies have shown that chemical restoration of  cell
UPR in type 1 diabetic mice results in a reduction in insulitis
(3).
Certain key limitations to our study must be recognized.
First, notwithstanding some evidence to the contrary, we can-
not rule out non- cell effects of pioglitazone in our study, and
it remains possible that  cell-protective effects may still indi-
rectly emanate from the effects on adipose tissue, muscle, or
immune cells. Second, the implications of our findings to
human T1D remain speculative, but recent observations sug-
gesting elevations in  cell ER stress parameters in human T1D
(3, 10, 25) suggest promise for the use interventions that
enhance the UPR. Although pioglitazone and similar TZDs
have fallen out of favor in clinical use, our findings linking
pioglitazone treatment to reductions in phospho-PPAR- (Ser-
273) open the exciting possibility that non-TZD approaches to
blocking Ser-273 phosphorylation may be an alternative
approach to enhancing the  cell UPR. Recently, imatinib
(Gleevec) was shown to block PPAR- (Ser-273) phosphoryla-
tion (50) and as such represents a non-TZDwith diabetes-ame-
liorating effects (50, 51). In this respect, an ongoing clinical trial
(NCT01781975) is testing the potential for imatinib as therapy
for recent-onset T1D. Taken together, our data support the
conclusion that TZDs and similar-acting agents may have pro-
tective effects to reduce  cell stress and death in T1D and also
support the notion that an aggressive approach to  cell func-
tion represents an important adjunctive means to control pro-
gression or severity of T1D.
FIGURE 5. Effect of pioglitazone on insulin secretion in pre-diabetic NOD mice. 6-Week-old pre-diabetic NOD mice were placed on either normal chow
(Control) or chow containing 0.01 wt% pioglitazone (Pio). A, serum insulin levels at the indicated time points after intraperitoneal glucose injection (2.0 g/kg
body weight) after 4 weeks of feeding (n 12 mice per group). B, glucose-stimulated insulin secretion from isolated islets from control and pioglitazone-fed
mice (n 9 mice per group). C, random-fed insulin levels after 4 weeks of feeding (n 8 mice per group). D, random-fed proinsulin levels after 4 weeks of
feeding (n 8mice per group). E, random-fed proinsulin:insulin ratio after 4weeks of feeding (n 8mice per group). * indicates value is significantly different
for the comparisons shown by two-tailed t test.
FIGURE 6. Effect of pioglitazone on  cell ER stress in pre-diabetic NOD
mice. 6-Week-old pre-diabetic NODmicewere placedon either normal chow
(Control) or chow containing 0.01 wt% pioglitazone (Pio). After 4 weeks of
feeding, pancreas was harvested (n 5) or islets were isolated and subjected
to RT-PCR (n  3 per group) or immunoblot analysis (n  3 per group). A,
splicedXbp1mRNA (relative toActbmRNA).B, immunoblot analysis andquan-
titation for ATF4. C, Gadd34 mRNA (relative to Actb mRNA). D, immunoblot
analysis and quantitation for Bip. E, Chop mRNA (relative to Actb mRNA). *
indicates that the values are significantly different (p 0.05) by two-tailed t
test.
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Experimental Procedures
Cells, Animals, and Procedures—Mouse-derived MIN6 
cellswere cultured andmaintained as previously described (52).
Pioglitazone and roscovitinewere dissolved inDMSOat 1000
concentration and applied directly to cell culture medium at
concentrations of 1 M or 10 M as indicated in the figures.
Cells were preincubated with pioglitazone or roscovitine over-
night before experimentation.
Female NOD/ShiLTJ (NOD)mice were purchased fromThe
Jackson Laboratory (Bar Harbor, ME) and maintained at the
Indiana University Laboratory Animal Resource Center under
pathogen-free conditions according to protocols approved by
the institutional animal care and use committee. Mice were
allowed to acclimate for 1 week before experimentation. Mice
were fed with either a standard chow diet or a standard chow
diet containing 0.01 wt% pioglitazone (Harlan-Teklad Global).
This concentration of pioglitazone was designed to deliver20
mg/kg body weight pioglitazone based on average daily food
intake (22, 39). Body weights and blood glucose levels were
measured weekly. At 10 weeks of age, mice underwent a intra-
peritoneal GTT at 2 g/kg body weight of glucose as described
previously (4). Serum during the GTT was collected for insulin
measurements at 0 and 10 min post glucose injection. Lean
body mass and fat mass was determined by dual-energy x-ray
absorptiometry (DEXA) using a Lunar PIXImus2 densitometer
(GE Medical Systems). Insulin tolerance tests were performed
with 1.5 units/kg body weight of insulin injected intraperitone-
ally as described (22). At the end of the study, mice were eutha-
nized, serum was collected, and pancreata harvested or islets
isolated as described (53). Serum insulinwasmeasured using an
Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem), and
serum proinsulin was measured using a Mouse Proinsulin
ELISA kit (ALPCO). Some mice were stimulated with 10
units/kg insulin (Humulin; Lilly) 5min before euthanasia, and
liver and muscle were harvested.
Quantitative Real-time RT-PCR and Immunoblot Analysis—
Total RNA from islets orMIN6 cells was isolated, reverse-tran-
scribed, and subjected to quantitative real-time RT-PCR as
described previously (54). Results of RT-PCRanalysiswere nor-
malized to Actb levels. Primers for mouse spliced Xbp1,
GADD34, Chop, and Actb were described previously (30,
55–58). Measurement of methylated and unmethylated pre-
proinsulin DNA in the serum bymultiplex PCRwas performed
as we recently detailed (31).
Immunoblots were performed using 4–20% polyacrylamide
gel electrophoresis as previously described (59). Antibodies
were used as follows: anti-phospho-AKT (Ser-473) (1:1000
dilution, Cell Signaling Technology #9271), anti-total AKT
(1:1000 dilution, Cell Signaling Technology #2920), anti-BIP
(1:1000 dilution, Cell Signaling Technology #3183), anti-ATF4
(1:500 dilution, Santa Cruz Biotechnology #sc-200), anti-actin
(1:1000 dilution, MP Biomedicals #691001), anti-GAPDH
(1:4000 dilution, Ambion #AM4300), anti-phospho-PPAR-
(Ser-273) (1:1000 dilution, Bioss #bs-4888R), and anti-acetyl
histone H3 (Lys14) (1:2000, Millipore #06-911).
Immunohistochemistry, Immunofluorescence,  Cell Area,
and Insulitis Scoring—Pancreata were fixed, sectioned, and
stained for insulin as described (22). Pancreata were stained for
immunofluorescence for glucagon, CHOP, PCNA, cleaved
caspase 3, or 4-HNEwith insulin and counterstainedwithDAPI
and quantified as described (4, 60). Images were captured using
an AxioObserver Z1 equipped with a high resolution color
FIGURE 7. Pioglitazone reduces oxidative stress, enhances  cell mass,
and suppresses  cell death in pre-diabetic NOD mice. 6-Week-old pre-
diabetic NOD mice were placed on either normal chow (Control) or chow
containing 0.01 wt% pioglitazone (Pio). After 4 of weeks feeding, pancreas
was harvested from animals (n 5). A, representative islet immunostaining
from control and pioglitazone-treated mice for CHOP and insulin and corre-
sponding quantitation of CHOPinsulin cells. Arrows indicate cells that
costain for insulin and CHOP. B, representative islet immunostaining for CC3
and insulin and correspondingquantitationof CC3insulin cells. Thearrow
indicates cells that costain for insulin and CC3. C, representative islet immu-
nostaining for 4-HNE and insulin and corresponding 4-HNE pixel intensity.D,
 cell area as a percentage of total pancreas area for animals at the start of the
study (6 weeks of age) and for control and pioglitazone treated at the indi-
cated ages. E, serum unmethylation index for control- and pioglitazone-
treated mice (n  4–5 per group). F, representative islet immunostaining
from control and pioglitazone-treated mice for PCNA and insulin and corre-
sponding quantitation of PCNAinsulin cells. Arrows indicate cells that
costain for insulin and PCNA. * indicates that the values are significantly dif-
ferent (p 0.05) by two-tailed t test.
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camera or LSM 700 confocal (Carl Zeiss).  cell area was calcu-
lated as described previously (61). For insulitis scoring, 3 pan-
creas sections at least 70 m apart from 5 animals per group
were scored using the following grading scheme (62): grade 1,
no islet-associated mononuclear cell infiltrates; grade 2, peri-
insulitis affecting50% of the circumference of the islet with-
out evidence of islet invasion; grade 3, peri-insulitis affecting
50% of the circumference of the islet with evidence of islet
invasion; grade 4, islet invasion.
Flow Cytometric Analysis of T Cells—Single cell suspensions
were prepared from harvested pancreatic lymph nodes from
NODmice (62, 63). For Treg cell analyses, equal volumes of the
single cell suspensions were stained using anti-CD4-FITC
(eBioscience RM4–5) and anti-CD25-APC (eBioscience
PC61.5) antibodies and fixed overnight before being permeabi-
lized and stained with anti-Foxp3-PE (eBioscience FJK-16s)
antibody. For the Th1 and Th17 cell analyses, equal volumes of
the single cell suspensions were first incubated with Cell Stim-
ulation Mixture (eBioscience) for 4 h before staining with
anti-CD4 antibody; cells were fixed overnight then permeabi-
lized and stained for IL-17A (eBioscience eBio17B7) and IFN
(eBioscience XMG1.2) according to the manufacturer’s in-
structions (eBioscience). Cells were analyzed using a BD
FACSCalibur flow cytometer (BDBiosciences) and FlowJo soft-
ware (TreeStar). For determination of cellular proliferation,
single cell suspensions of unfractionated splenocytes from
NODmicewere incubated in 5Mmembrane dye carboxyfluo-
rescein diacetate succinimidyl ester (CFSE) for 10 min at 37 °C,
diluted with 5 volumes of ice-cold media, and incubated for 5
min on ice. Sampleswere thenwashedwith PBS three times and
subjected to stimulation in vitro and subjected to flow cytom-
etry as described above.
Statistical Analysis—All data are presented as the mean 
S.E. One-way analysis of variance (with Dunnett’s post-test)
was used for comparisons involving more than two conditions,
and a two-tailed Student’s t test was used for comparisons
involving two conditions. Prism 7 software (GraphPad) was
used for all statistical analyses. Statistical significance was
assumed at p 0.05.
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